A case of progressive renal impairment diagnosed by colon biopsy.

Nephrology (Carlton)

Manly Hospital, Sydney, New South Wales, Australia.

Published: July 2016

Download full-text PDF

Source
http://dx.doi.org/10.1111/nep.12648DOI Listing

Publication Analysis

Top Keywords

case progressive
4
progressive renal
4
renal impairment
4
impairment diagnosed
4
diagnosed colon
4
colon biopsy
4
case
1
renal
1
impairment
1
diagnosed
1

Similar Publications

Background: Radiation-induced sarcoma (RIS) is an exceptionally rare occurrence following radiation therapy, and manifestation usually occurs after a several-year latency period. Herein, the authors report the development of a radiation-induced osteosarcoma of the frontoparietal calvaria following treatment for an oligodendroglioma in an 84-year-old woman.

Observations: The patient had been diagnosed with a grade III anaplastic oligodendroglioma when she was 78 years old.

View Article and Find Full Text PDF

Atypical mycobacteria can cause rare and atypical infections of the hand. We report the case of an immunocompetent 46-year-old male initially presenting with thumb felon and progressively developing symptoms of carpal tunnel syndrome, tenosynovitis of multiple fingers and a sporotrichoid lymphocutaneous infection causing chronic cutaneous lesions all over the body. We would like to highlight the diagnostic and therapeutic difficulties of these atypical infections, which mimic other conditions and can cause a lot of morbidity.

View Article and Find Full Text PDF

Chryseobacterium indologenes is a rare human pathogen which is nowadays considered an emerging fearsome organism because of its upcoming antibiotic resistance. We present a quite unique case of a multi drug resistant C. indologenes surgical wound infection in a patient submitted to cannulated screw fixation of a displaced medial malleolus fracture.

View Article and Find Full Text PDF

Purpose: Outcomes for patients with advanced sarcomas are poor and there is a high unmet need to develop novel therapies. The purpose of this phase I study was to define the safety and efficacy of botensilimab (BOT), an Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, in advanced sarcomas.

Methods: BOT was administered intravenously (IV) at 1 mg/kg or 2 mg/kg once every 6 weeks in combination with BAL IV at 3 mg/kg once every 2 weeks for up to 2 years.

View Article and Find Full Text PDF

Subungual melanoma accounts for 1.9% of cutaneous melanomas. Amelanotic cases, comprising 15-25%, poses a significant diagnostic challenge because it can be misdiagnosed as other traumatic, inflammatory, or neoplastic conditions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!